Inhibikase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share

Net Loss Per Share

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share

12. Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:


	Year ended December 31,
	2022			2021
Numerator:
Net loss	$	(18,054,155	)	$	(14,786,063	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		25,211,726			18,209,198
Net loss per share applicable to common stockholders – basic and diluted	$	(0.72	)	$	(0.81	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Year ended December 31,
	2022		2021
Options to purchase shares of stock		4,394,369		3,596,444
Warrants to purchase shares of stock		1,561,913		1,561,913
Total		5,956,282		5,158,357